Skip to content

A Study on Oma ilagam (Internal)and Kunthirika Thylam ( External) in the management of Kaanakadi(Urticaria)

An open clinical Trial to evaluate the Effectiveness of Siddha formulation Oma Ilagam(Internal Medicine) and Kunthirika Thylam( External Medicine) in the management of Kaanakadi(Urticaria) - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080785
Enrollment
30
Registered
2025-02-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L50- Urticaria

Interventions

Intervention1: Oma Ilagam(Internal) and Kunthirika Thylam(External): Internal 5g bid with hot water after food external medicine apply on the affected area for 40days Control Intervention1: NIL: NIL

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinical diagnosis of erythematous wheal formation urticaria with UAS Score patients willing and able to to provide informed consent and to comply with the study protocol patients willing to stop using any treatment other than the investigational product for urticaria

Exclusion criteria

Exclusion criteria: Pregnant or lactation women Evidence of any skin condition other than urticaria Narcotic addicts and Angioneurotic oedema Other medications or disease that might directly interfere in the study

Design outcomes

Primary

MeasureTime frame
Efficacy of the Trail Drug is measured using Urticaria Activity Score UASTimepoint: Changes in the Urticaria Activity Score will be assessed before and after treatment along with blood parameters after 40 day of Trail Period

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Dharmar M

National Institute of Siddha

drmadhavanji@gmail.com9965561656

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026